The Vapor Technology Association (VTA) met with officials from the U.S. Food and Drug Administration's Center for Tobacco Products (CTP) on May 2 to help clarify issues related to synthetic nicotine. The premarket Tobacco Product Application (PMTA) for synthetic products expires on May 14.
"We have presented a thoughtful case for synthetic nicotine products that, to our knowledge, has not been presented to any policy maker," the VTA wrote in a press release.
During the meeting, scientists explained how synthetic nicotine is made and how it differs from tobacco-derived nicotine. Expert speakers include Bill Jackson (Organic Chemistry), David Johnson (Physical analytical chemistry), Ray McCague (Organic Chemistry) and Willie McKinney (inhalation toxicology).
This is the VTA's second meeting since it signed new synthetic nicotine legislation with the FDA. While satisfied with the level of involvement of the CTP, the VTA stressed that its work was continuing.
"These meetings, along with others we are conducting, are just one part of VTA's multi-pronged strategy to ensure a proper and comprehensive evaluation of synthetic nicotine PMTA," the VTA wrote.
"If your company is producing products containing synthetic nicotine and attaches great importance to the regulatory compliance, or retail business if you want to be able to continue through synthetic nicotine products to diversify its retail products, or if you want to continue to be innovative products containing synthetic nicotine nicotine, you should strongly consider participating in our strategic work."

